Treatment of Ovarian Cancer in Malignant Sex Cord-Stromal Tumor of the Ovary

Malignant sex cord-stromal tumors represent a distinct subtype of ovarian cancer with specific management considerations that set them apart from the more common epithelial histologies. Selecting the right approach for this population requires tailored clinical decision-making.

Clinical Scenario

This protocol addresses ovarian cancer arising as a malignant sex cord-stromal tumor — a subtype whose biology and treatment response differ meaningfully from other ovarian malignancies, warranting a dedicated evidence-based pathway.

Treatment Approach (Partial Overview)

Management in this setting may involve surgical reassessment together with systemic options spanning chemotherapy regimens and hormonal therapy approaches — the full selection criteria, preferred agents, and sequencing algorithm are contained in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

Malignant sex cord-stromal tumors
Carboplatin/Paclitaxel
Docetaxel
Ifosfamide/Paclitaxel
Paclitaxel
Targeted therapy: Bevacizumab (single agent)
Aromatase inhibitors (eg, Anastrozole, Exemestane, Letrozole)
Leuprolide acetate or Goserelin acetate (for granulosa cell tumors)
Tamoxifen

View source ↗